Evidence map›Paper›PMID 28050642›Full record

Trial reportWorld journal of urology2017

Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms.

Mohamed H Abdelhamid, Ahmed S Zayed, Waleed E Ghoneima, Akrm A Elmarakbi, Mohamed S El Sheemy, Ahmed Aref, Ahmed Abdelbary, Hani H Nour

Abstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Pharmacological treatment of bladder stent symptoms.Bladder (San Francisco, Calif.) · 2024
    Review
  6. Article
  7. Ureteral Stent Discomfort and Its Management.Current urology reports · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mohamed H AbdelhamidDepartment of Urology, Cairo University, Cairo, 11562, Egypt. haythamuro@yahoo.com.
Ahmed S ZayedDepartment of Urology, Theodor Bilharz Research Institute, Giza, 12411, Egypt.
Waleed E GhoneimaDepartment of Urology, Cairo University, Cairo, 11562, Egypt.
Akrm A ElmarakbiDepartment of Urology, Beni-Suef University, Beni Suef, 62511, Egypt.
Mohamed S El SheemyDepartment of Urology, Cairo University, Cairo, 11562, Egypt.
Ahmed ArefDepartment of Urology, Beni-Suef University, Beni Suef, 62511, Egypt.
Ahmed AbdelbaryDepartment of Urology, Beni-Suef University, Beni Suef, 62511, Egypt.
Hani H NourDepartment of Urology, Theodor Bilharz Research Institute, Giza, 12411, Egypt.
Beni-Suef University · EGCairo University · EGTheodor Bilharz Research Institute · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to compare the safety and efficacy of solifenacin versus trospium chloride and compare each drug versus placebo regarding the relief of stent-related symptoms following uncomplicated ureteroscopic lithotripsy (URSL).

methodsIn a prospective, randomized, double-blind study, 210 eligible patients who underwent URSL with double-J stent insertion were recruited and randomly assigned to either the first group, receiving solifenacin (10 mg), second group, receiving trospium chloride (60 mg), or the third group, receiving placebo (one tablet). All patients were kept on study medication once daily during the entire 2-week postoperative period. All subjects were asked to complete a brief-form questionnaire to assess the lower urinary symptoms, stent-related body pain and hematuria, preoperatively and 2 weeks postoperatively.

resultsThere were no statistically significant differences among the study groups in terms of mean age, gender, anthropometric measurements, stone and stent criteria. The overall symptom score, urgency, urge incontinence, flank pain, urethral pain and gross hematuria scores were significantly lower in solifenacin group compared to trospium chloride and placebo groups (p < 0.001). Concerning frequency and nocturia, there was no significant difference in mean scores across all groups. Drug-related side effects, particularly constipation, were higher in trospium group than in solifenacin one.

conclusionsSolifenacin treatment showed significant improvement in almost all domains of stent-related symptoms than trospium. In terms of safety and tolerance, both drugs were comparable. Future studies should be designed to address the impact of combined drugs and lower doses in the management of DJ stent-related symptoms.

Indexed as

StentsAdolescentAdultAgedBenzilatesDouble-Blind MethodFemaleFlank PainHematuriaHumansKidney CalculiLithotripsyMaleMiddle AgedMuscarinic AntagonistsNocturiaBenzilatesMuscarinic AntagonistsNortropanesSolifenacin Succinatetrospium chlorideLaser lithotripsySolifenacinStent-related symptomsTrospium chlorideUreteroscopy

Identifiers

PMID28050642
OpenAlexW2565539993

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.